Cardiology
First-Ever Guideline on Cardiovascular-Kidney-Metabolic Syndrome Issued
The American Heart Association and the American College of Cardiology released the first clinical practice guideline on cardiovascular-kidney-metabolic (CKM) syndrome, emphasizing early screening and coordinated care to address interconnected heart, kidney, and metabolic conditions affecting nearly 90% of U.S. adults.
HeartBeam Study Shows Portable ECG Device Can Help Identify Heart Attack Risk
A peer-reviewed study published in JACC: Advances demonstrates that HeartBeam's credit card-sized ECG device, combined with a risk prediction algorithm, can accurately identify heart attack risk in patients with chest pain, potentially enabling earlier detection and treatment.
HeartBeam's Portable ECG Device Shows Promise in Identifying Heart Attack Risk, Study Finds
A peer-reviewed study published in JACC: Advances demonstrates that HeartBeam's credit card-sized ECG device, combined with a risk prediction algorithm, can accurately identify heart attack risk in chest pain patients, with accuracy rising to 92.9% when a baseline ECG is available.
HeartBeam Aims to Close Critical Gap in Early Cardiac Detection with Portable ECG System
HeartBeam is developing a cable-free, portable ECG system to address pre-hospital delays in cardiac care by enabling clinical-grade data collection outside clinical settings.
HeartBeam Aims to Close Critical Gap in Early Cardiac Detection with Portable ECG Platform
HeartBeam Inc. is developing a cable-free, high-fidelity ECG platform to address pre-hospital delays in cardiac care, with potential for future heart attack detection.
Cardio Diagnostics Aims to Transform Heart Care with AI-Driven Personalized Medicine
Cardio Diagnostics Holdings is advancing a vision to shift cardiovascular care from reactive treatment to early prevention using AI, epigenetics, and genetic insights, aiming to reduce the global burden of heart disease.
Cardio Diagnostics Leverages AI and Epigenetics to Address Preventable Cardiovascular Disease
Cardio Diagnostics Holdings offers AI-powered solutions for cardiovascular disease prevention, targeting the 80% of cases considered preventable through earlier detection and personalized intervention.
Wearable Wristband Shows Promise in Detecting Cardiac Arrest, Study Finds
New research published in Circulation: Arrhythmia and Electrophysiology demonstrates that a smart wristband using photoplethysmography can detect cardiac arrest with 92% accuracy in a clinical setting, potentially enabling faster emergency response and improved survival for out-of-hospital cardiac arrest.
Cardio Diagnostics Advances Personalized Heart Care Through AI and Epigenetics
Cardio Diagnostics Holdings is leveraging AI, epigenetics, and genetic insights to shift cardiovascular care from reactive treatment to predictive prevention, addressing heart disease as the leading cause of death worldwide.
HeartBeam Advances Commercial Launch, Reports Improved Q1 2026 Results
HeartBeam reported first-quarter 2026 results highlighting initial commercial partnerships in key U.S. markets and an $11.5 million public offering, as it advances its FDA-cleared 3D ECG platform for heart attack detection and ambulatory monitoring.
HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch Aimed at Ischemia Detection
HeartBeam Inc. has initiated a pilot study for its investigational on-demand 12-lead ECG patch in coronary artery disease patients, potentially expanding ambulatory cardiac monitoring into ischemia detection within a $2 billion market.
HeartBeam Expands Concierge Cardiology Footprint with Atelier Health Agreement
HeartBeam Inc. has signed a commercial agreement with Beverly Hills-based Atelier Health, expanding its launch footprint into Southern California and completing its initial targeted markets for its cable-free 3D ECG technology.
HeartBeam Targets Heart Disease with Advanced ECG Technology as Cardiovascular Deaths Surge
HeartBeam Inc. is developing next-generation ECG solutions to address the gap in early cardiac detection, as cardiovascular disease remains the leading cause of death in the U.S. with over 919,000 deaths in 2023.
New Book Aims to Close Awareness Gap on Women's Heart Disease Symptoms
Cardiologist Arash Bereliani releases 'What About Her Heart' to educate the public on how heart disease presents differently in women, addressing a critical gap in recognition and timely diagnosis.
Ventripoint to Showcase AI-Powered Cardiac Imaging at European Paediatric Cardiology Conference
Ventripoint will exhibit its VMS+ 4.0 technology at the AEPC annual meeting, highlighting its potential to improve lifelong care for congenital heart disease patients through accurate, MRI-equivalent assessments from echocardiograms.
Cardio Diagnostics Harnesses AI and Biomarkers to Combat Heart Disease Burden
Cardio Diagnostics Holdings is advancing early detection of cardiovascular disease using an AI-powered platform that analyzes epigenetic and genetic biomarkers from a simple blood sample, addressing the leading cause of death in the U.S.
Cardio Diagnostics Targets Precision Cardiology with Multi-Omic AI Platform
Cardio Diagnostics Holdings (NASDAQ: CDIO) leverages AI to integrate epigenetic and genetic biomarkers for personalized cardiovascular risk assessments, potentially transforming disease prevention and treatment.
Ventripoint's AI-Powered Cardiac Imaging System Submitted for Expedited Approval in China
Ventripoint Diagnostics announced that its VMS+ 4.0 system has been submitted for regulatory approval in China via an expedited 'green channel' pathway, potentially accelerating access to AI-driven cardiac diagnostics in a market with 330 million cardiovascular patients.
Advanced Heart, Kidney and Metabolic Syndrome Linked to 30% Higher Cancer Risk, Study Finds
New research published in Circulation: Population Health and Outcomes reveals that later stages of cardiovascular-kidney-metabolic (CKM) syndrome are associated with a 25-30% increased risk of cancer, highlighting the need for integrated screening.
HeartBeam Partners with Mount Sinai to Develop AI-Driven ECG Algorithms
HeartBeam's collaboration with Mount Sinai aims to advance AI-enabled ECG analysis, reinforcing its role in the shift toward data-driven remote cardiac monitoring.
HeartBeam Partners with Mount Sinai to Develop AI-Powered ECG Algorithms
HeartBeam Inc. collaborates with Mount Sinai to advance AI-driven ECG technology, aiming to enhance remote cardiac monitoring and chronic condition management.
American Heart Association Mourns Passing of Pioneering Cardiologist Eugene Braunwald
The American Heart Association honors the legacy of Dr. Eugene Braunwald, whose seven decades of research transformed cardiovascular medicine, and highlights his enduring influence through mentorship and the Eugene Braunwald Academic Mentorship Award.
HeartBeam Announces Public Offering to Fund Cardiac Technology Commercialization and AI Development
HeartBeam Inc. is launching a public offering to finance the commercialization of its FDA-cleared 12-lead ECG system and advance AI initiatives for cardiac care.
HeartBeam Closes $10 Million Public Offering to Accelerate Cardiac Tech Commercialization
HeartBeam Inc. raised $10 million in a public offering to fund the commercialization of its FDA-cleared 12-lead synthesized ECG system and other cardiac technologies.
HeartBeam Closes $10M Public Offering to Fund Commercialization of ECG Technology
HeartBeam raised $10 million in a public offering to advance its FDA-cleared 12-lead synthesized ECG system and heart attack detection technologies, positioning the company for expanded market reach.
BioXgen Seeks Crowdfunding Investment for Cardiac Patch Targeting Post-Surgery Complication
BioXgen is launching a Regulation Crowdfunding investment round and hosting a webinar to demonstrate its cardiac patch designed to prevent postoperative atrial fibrillation, a common complication affecting nearly half of open-heart surgery patients.
HeartBeam Partners with HeartNexus to Expand Remote Cardiac Diagnostic Access
HeartBeam's collaboration with HeartNexus enables 24/7 cardiologist access for remote ECG interpretation, addressing critical gaps in cardiovascular care accessibility worldwide.
Polypill Strategy Shows Promise for Heart Failure Treatment, Improving Outcomes and Medication Adherence
A new study demonstrates that a once-daily combination pill for heart failure patients significantly improves heart function, reduces hospitalizations, and enhances quality of life compared to traditional multi-pill regimens.
PCSK9 Inhibitor Combined with Statin Shows Significant LDL Reduction in Heart Transplant Patients
A clinical trial demonstrates that adding the PCSK9 inhibitor alirocumab to statin therapy reduces LDL cholesterol by more than 50% in heart transplant patients, though it did not prevent the development of cardiac allograft vasculopathy.
Stress Cardiac MRI Testing Improves Angina Diagnosis and Patient Outcomes, Study Finds
New research presented at the American Heart Association's Scientific Sessions 2025 demonstrates that stress cardiac MRI testing significantly improves diagnosis accuracy and quality of life for patients with chest pain despite clear coronary arteries.